PRiME was established at the University of Toronto to align research efforts in the area of Precision Medicine.
PRiME brings together multi-disciplinary talent to face and answer emerging challenges in Precision Medicine by understanding the biology of disease, creating new tools for disease diagnosis, and developing novel therapeutic strategies.
Mission:
Grow interdisciplinary international research, training and translation pipelines that propel promising therapeutics towards patients.
Vision:
Build inclusive, interdisciplinary global research hubs that redefine how next-generation precision medicine is discovered, developed, and delivered.
Strategic Priorities:
- Catalyze first-in-class research by enabling deep interdisciplinary collaborative research across
- drug discovery, delivery, diagnostics, computation, and disease biology, and embedding ideasto-
- impact pathways from project inception.
- Foster entrepreneurship towards venture creation and growth.
- Drive translational outcomes through seamless integration with affiliated hospitals,
- commercialization partners, and industry throughout the research lifecycle.
- Strengthen training and talent development that integrates scientific excellence with
- translational, entrepreneurial, and industry-relevant skills.
- Embed Equity, Diversity, & Inclusion best practices across all Precision X hubs.
Precision X
Precision X is PRiME’s flagship effort to transform how precision therapeutics are discovered, developed and delivered.
PRiME’s Precision X hubs focus on Precision Aging, Precision Oncology, and Precision Women’s Health, areas where complexity, heterogeneity, and unmet need demand deeply interdisciplinary and translational approaches.
Each global hub brings together expertise in AI/ML, computational biology, drug discovery, delivery, and diagnostics, with embedded research translation and entrepreneurship to ensure real-world impact.
The current focus areas include:
- Precision Aging
- Precision Oncology
- Precision Women’s Health
[PRiME is] an ambitious and groundbreaking collaborative initiative at the frontiers of medical research and innovation. It is the kind of initiative needed to tackle complex research problems and to undertake the clinical translation and commercialization that are so criticial to have lasting impact.
Meric Gertler
President of the University of Toronto.